134 related articles for article (PubMed ID: 9293904)
41. The role of O6-alkylguanine DNA alkyltransferase in limiting nitrosourea-induced sister chromatid exchanges in proliferating human lymphocytes.
Trey JE; Gerson SL
Cancer Res; 1989 Apr; 49(8):1899-903. PubMed ID: 2702633
[TBL] [Abstract][Full Text] [Related]
42. Transcriptional repression of O6-methylguanine DNA methyltransferase gene rendering cells hypersensitive to N,N'-bis(2-chloroethyl)-N-nitrosurea in camptothecin-resistant cells.
Ma LC; Kuo CC; Liu JF; Chen LT; Chang JY
Mol Pharmacol; 2008 Aug; 74(2):517-26. PubMed ID: 18492797
[TBL] [Abstract][Full Text] [Related]
43. Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells.
Fontes AM; Davis BM; Encell LP; Lingas K; Covas DT; Zago MA; Loeb LA; Pegg AE; Gerson SL
Mol Cancer Ther; 2006 Jan; 5(1):121-8. PubMed ID: 16432170
[TBL] [Abstract][Full Text] [Related]
44. Introduction of the green fluorescent protein gene into hematopoietic stem cells results in prolonged discrepancy of in vivo transduction levels between bone marrow progenitors and peripheral blood cells in nonhuman primates.
Hanazono Y; Terao K; Shibata H; Nagashima T; Ageyama N; Asano T; Ueda Y; Kato I; Kume A; Hasegawa M; Ozawa K
J Gene Med; 2002; 4(5):470-7. PubMed ID: 12221639
[TBL] [Abstract][Full Text] [Related]
45. Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance.
Koç ON; Allay JA; Lee K; Davis BM; Reese JS; Gerson SL
Semin Oncol; 1996 Feb; 23(1):46-65. PubMed ID: 8607032
[TBL] [Abstract][Full Text] [Related]
46. Eradication of human medulloblastoma tumor xenografts with a combination of O6-benzyl-2'-deoxyguanosine and 1,3-bis(2-chloroethyl)1-nitrosourea.
Kokkinakis DM; Moschel RC; Pegg AE; Schold SC
Clin Cancer Res; 1999 Nov; 5(11):3676-81. PubMed ID: 10589786
[TBL] [Abstract][Full Text] [Related]
47. MGMT expression in murine bone marrow is a major determinant of animal survival after alkylating agent exposure.
Reese JS; Qin X; Ballas CB; Sekiguchi M; Gerson SL
J Hematother Stem Cell Res; 2001 Feb; 10(1):115-23. PubMed ID: 11276365
[TBL] [Abstract][Full Text] [Related]
48. SarCNU mediates selection of P140K methylguanine-DNA-methyltransferase transduced human CD34(+) cells in vitro.
Zielske SP; Gerson SL
Blood Cells Mol Dis; 2003; 31(1):48-50. PubMed ID: 12850483
[TBL] [Abstract][Full Text] [Related]
49. Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients.
Bowman JE; Reese JS; Lingas KT; Gerson SL
Mol Ther; 2003 Jul; 8(1):42-50. PubMed ID: 12842427
[TBL] [Abstract][Full Text] [Related]
50. Lentivirus-mediated expression of mutant MGMTP140K protects human CD34+ cells against the combined toxicity of O6-benzylguanine and 1,3-bis(2-chloroethyl)-nitrosourea or temozolomide.
Chinnasamy D; Fairbairn LJ; Neuenfeldt J; Treisman JS; Hanson JP; Margison GP; Chinnasamy N
Hum Gene Ther; 2004 Aug; 15(8):758-69. PubMed ID: 15319033
[TBL] [Abstract][Full Text] [Related]
51. Human-yeast chimeric repair protein protects mammalian cells against alkylating agents: enhancement of MGMT protection.
Roth TJ; Xu Y; Luo M; Kelley MR
Cancer Gene Ther; 2003 Aug; 10(8):603-10. PubMed ID: 12872142
[TBL] [Abstract][Full Text] [Related]
52. Modulation of nitrosourea resistance in myeloid leukemias.
Gerson SL; Trey JE
Blood; 1988 May; 71(5):1487-94. PubMed ID: 3258773
[TBL] [Abstract][Full Text] [Related]
53. A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase.
Cornetta K; Croop J; Dropcho E; Abonour R; Kieran MW; Kreissman S; Reeves L; Erickson LC; Williams DA
Cancer Gene Ther; 2006 Sep; 13(9):886-95. PubMed ID: 16645619
[TBL] [Abstract][Full Text] [Related]
54. Selection of genetically modified hematopoietic cells in vitro and in vivo using alkylating agent lysomustine.
Rozov FN; Grinenko TS; Levit GL; Krasnov VP; Belyavsky AV
Anal Biochem; 2010 Sep; 404(2):149-54. PubMed ID: 20450874
[TBL] [Abstract][Full Text] [Related]
55. DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors.
Kuo CC; Liu JF; Chang JY
J Pharmacol Exp Ther; 2006 Feb; 316(2):946-54. PubMed ID: 16258022
[TBL] [Abstract][Full Text] [Related]
56. Specificity of bischloroethylnitrosourea-induced mutation in a Chinese hamster ovary cell line transformed to express human O6-alkylguanine-DNA alkyltransferase.
Minnick DT; Gerson SL; Dumenco LL; Veigl ML; Sedwick WD
Cancer Res; 1993 Mar; 53(5):997-1003. PubMed ID: 8439973
[TBL] [Abstract][Full Text] [Related]
57. Cell-cycle, phase-specific cell killing by carmustine in sensitive and resistant cells.
Linfoot PA; Barcellos-Hoff MH; Brent TP; Marton LJ; Deen DF
NCI Monogr; 1988; (6):183-6. PubMed ID: 3352762
[TBL] [Abstract][Full Text] [Related]
58. Retroviral transduction of a mutant methylguanine DNA methyltransferase gene into human CD34 cells confers resistance to O6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea.
Reese JS; Koç ON; Lee KM; Liu L; Allay JA; Phillips WP; Gerson SL
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14088-93. PubMed ID: 8943065
[TBL] [Abstract][Full Text] [Related]
59. In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication.
Davis BM; Humeau L; Dropulic B
Mol Ther; 2004 Feb; 9(2):160-72. PubMed ID: 14759800
[TBL] [Abstract][Full Text] [Related]
60. Nuclear-localizing O6-benzylguanine-resistant GFP-MGMT fusion protein as a novel in vivo selection marker.
Choi U; DeRavin SS; Yamashita K; Whiting-Theobald N; Linton GF; Loktionova NA; Pegg AE; Malech HL
Exp Hematol; 2004 Aug; 32(8):709-19. PubMed ID: 15308322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
